Clinical Trials Browser

Phase 1 × SNX-5422 × Other hematologic neoplasm × Clear all

NCT02914327 2018-07-30

Safety and Activity of SNX-5422 Plus Ibrutinib in CLL

Phase 1 Withdrawn

LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01635712 2017-04-26

Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies

Phase 1 Completed

Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms

NCT00595686 2012-05-17

Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies

Phase 1 Completed

Other hematologic neoplasm

Hematologic Neoplasms